Previous issue | Volume 84 | ESPE2015 | Next issue

54th Annual ESPE

Barcelona, Spain
01 Oct 2015 - 03 Oct 2015

Card image cap
Barcelona, Spain; 1-3 October 2015 Further information

Poster Category 2

GH & IGF

Unaltered Ratio of Circulating Levels of GH Isoforms after Administration of Different GH Provocative Tests in a Population of Short Stature Children
aUniversity of Milan, Milan, Italy; bUniversity of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; cMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany; dFondazione IRCCS Policlinico San Matteo, Pavia, Italy
hrp0084p2-392
Gene Expression Profiles in GH Deficient Children Relate Peak GH Levels to Circadian Clock, Chromatin Remodelling, and WNT Signalling Pathways
aFaculty of Medical and Human Sciences, Institute of Human Development, Royal Manchester Children’s Hospital, University of Manchester and Manchester Academic Health Science Centre, Central Manchester, Manchester, UK; bMerck Serono, Darmstadt, Germany; cDepartment Pediatrie, Hôpital Mère-Enfant, Université Claude Bernard, Lyon, France
hrp0084p2-394
Growth and GH in Kabuki Syndrome
aAtrium-Orbis Medical Centre, Heerlen, The Netherlands; bMaastricht University Medical Centre, Maastricht, The Netherlands
hrp0084p2-395
Abstract unavailable
hrp0084p2-396
Silver Russell syndrome: A Cause of Partial IGF1 Resistance?
aAP-HP, Hôpital Armand Trousseau, Explorations Fonctionnelles Endocriniennes, F-75012 Paris, France; bSorbonne Universités, UPMC University Paris 06, F-75005 Paris, France
hrp0084p2-397
The In vitro Functional Analysis of Gene Promoter Region Single Nucleotide Polymorphisms Associated with GH Response in Children with GH Deficiency
Faculty of Medical and Human Sciences, Institute of Human Development, University of Manchester and Manchester Academic Health Science Centre, Royal Manchester Children’s Hospital, Manchester, UK
hrp0084p2-398
Is Retesting in GH Deficient Children Really Useful?
aUniversity of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; bFondazione IRCCS Policlinico San Matteo, Pavia, Italy; cUniversity of Brescia, Brescia, Italy; dUniversity of Brescia, Spedali Civili, Brescia, Italy; eOspedale ‘Carlo Poma’, Mantova, Italy
hrp0084p2-399
GRB10 Knockdown in Zebrafish is Associated with Decreased Weight-to-length Ratio without Alterations in AKT and ERK Activity: A Model to Study Human Growth Regulation
aFaculty of Medical and Human Sciences, Institute of Human Development, University of Manchester and Manchester Academic Health Science Centre, Royal Manchester Children’s Hospital, Manchester, UK; bFaculty of Life Sciences, University of Manchester, Manchester, UK
hrp0084p2-401
Homozygous Carriers of a Novel IGFALS Mutation are 1.5 SD Shorter than Heterozygous Relatives and Tend to have Lower Bone Mineral Density
aPediatric Endocrinology, Gaziantep Children’s Hospital, Gaziantep, Turkey; bSection Metabolic Diseases, Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands; cFaculty of Medicine, Pediatric Endocrinology, Hacettepe University, Ankara, Turkey; dDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; eDepartment of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands
hrp0084p2-403
The Role of [beta]-TrCP, an E3 Ubiquitin Ligase, in the Signalling of the GH and Epidermal Growth Factor Pathways in Growth Hormone Transduction Defect
aDepartment of Paediatrics, Division of Paediatric Endocrinology and Diabetes, Paediatric Endocrine Research Laboratory, University of Patras School of Medicine, Patras, Greece; bFaculty of Human Movement and Quality of Life Sciences, Department of Nursing, University of Peloponnese, Sparta, Greece
hrp0084p2-404
SGA Short Stature Bearing with a Novel Nonsense Mutation (p.W1249X) in the IGF1R Gene
aTottori University, Yonago, Japan; bAichi Children’s Health and Medical Center, Obu, Japan
hrp0084p2-405
Metabolic Health in Short Children Born Small for Gestational Age Treated with GH and GnRHa: Results of a Randomised, Dose-response Trial
aDutch Growth Research Foundation, Rotterdam, The Netherlands; bChildren’s Hospital Erasmus MC-Sophia, Rotterdam, The Netherlands; cUniversity Medical Center Groningen, Groningen, The Netherlands; dZaans Medisch Centrum, Zaandam, The Netherlands; eRijnstate Hospital, Arnhem, The Netherlands; fRadboud University Medical Center, Nijmegen, The Netherlands; gCatharina Hospital, Eindhoven, The Netherlands; hLeiden University Medical Center, Leiden, The Netherlands; iIsala Clinics, Zwolle, The Netherlands; jAdmiraal de Ruyter Hospital, Vlissingen, The Netherlands; kCanisius Hospital, Nijmegen, The Netherlands
hrp0084p2-406
A Phase 2, 6-Month, Randomised, Active-Controlled, Safety and Efficacy Study of TransCon hGH Compared to Daily Human GH in Children with GH Deficiency
aUniversity Claude Bernard, Lyon, France; bBashkir State Medical University, Ufa, Russia; cSecond Children City Clinic, Minsk, Belarus; dKharkiv National Medical University, Kharkiv, Ukraine; eAscendis Pharma A/S, on behalf of the TransCon hGH study group, Hellerup, Denmark
hrp0084p2-407
Does Skeletal Disproportion in Children with Idiopathic Short Stature Influence Response to GH Therapy?
aPediatric Endocrinology, Liggins Institute, University of Auckland, Auckland, New Zealand; bPfizer Health AB, Sollentuna, Sweden; cCenter for Endocrinology, Diabetes, and Metabolism, The Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, CA, USA; dEndocrine Care, Pfizer Inc., New York, NY, USA
hrp0084p2-408
Response to GH Treatment in the Very Young with GH Deficiency
aDr Sami Ulus Obstetrics and Gynecology, Children’s Health and Disease Training and Research Hospital, Ankara, Turkey; bIstanbul Faculty of Medicine, Pediatric Endocrinology Unit, Institute of Child Health, Istanbul University, Istanbul, Turkey; cFaculty of Medicine, Yildirim Beyazit University, Ankara, Turkey; dDepartment of Pediatric Endocrinology, Ankara University School of Medicine, Ankara, Turkey; eDepartment of Pediatric Endocrinology, Marmara University, Istanbul, Turkey; fCerrahpasa Medical Faculty, Pediatrics Department, Pediatric Endocrinology and Adolescent Divisions, Istanbul University, Istanbul, Turkey; gFaculty of Medicine, Division of Pediatric Endocrinology, Cukurova University, Adana, Turkey; hDepartment of Endocrinology, Ankara Children’s Hematology and Oncology Training Hospital, Ankara, Turkey; iDepartment of Pediatric Endocrinology, Ege University School of Medicine, Izmir, Turkey
hrp0084p2-410
Estimation of Adipsin, Omentin and Vaspin Concentration in Prepubertal Children with GH Deficiency before and after 6 Months of GH Treatment
aChildren’s Memorial Health Institute, Warsaw, Poland; bUniversity of Jan Kochanowski, Kielce, Poland
hrp0084p2-411
Final Height and Safety Outcomes in GH-Treated Children Born Small for Gestational Age: Experience from the Prospective GeNeSIS Observational Study
aEli Lilly and Company, Windlesham, UK; bSydney Children’s Hospital, Randwick, NSW, Australia; cEli Lilly and Company, Indianapolis, IN, USA; dUniversity of Montreal and CHU Ste-Justine, Montreal, Canada; eDepartment of Pediatrics, Thomas Jefferson University, Philadelphia, PA, USA; fUniversity of Cologne, Children’s Hospital, Cologne, Germany; gUniversity of Giessen, University Children’s Hospital, Giessen, Germany
hrp0084p2-412
Results up to January 2015 from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope[reg] in Children Requiring GH Treatment
aUniversity of Leipzig Medical School, Leipzig, Germany; bRoyal Alexandra Children’s Hospital, Brighton, UK; cKarolinska University Hospital, Stockholm, Sweden; dUmeå University, Umeå, Sweden; eSandoz International GmbH, Holzkirchen, Germany; fUniversity Children’s Hospital, Llubljana, Slovenia; g25 rue Boudet, Bordeaux, France
hrp0084p2-413
GH Treatment Prevents Hypoxia-Induced Decrease of GH and IGF1 Plasma Concentrations in Neonatal Mice
aDepartment of Pediatrics and Adolescent Medicine, Division of Neuropediatrics, University Hospital Erlangen, Erlangen, Germany; bDepartment of Pediatrics and Adolescent Medicine, Division of Pediatric Endocrinology, University Hospital Erlangen, Erlangen, Germany
hrp0084p2-414
The Pharmacokinetics and Pharmacodynamics of TV-1106, a Once Weekly GH Supplement: Results from a Phase 2 Study of TV-1106 in Adults with GH Deficiency
aPharmacokinetics and Phase 1 Studies Teva Pharmaceuticals, Netanya, Israel; bDepartment of Endocrinology, MEA, Aarhus University Hospital NBG, Aarbus, Denmark; cMedizinische Klinik und Poliklinik IV, Ludwig-Maximilian-University of Munich, Munich, Germany; dClinical Development Teva Pharmaceuticals Ltd, Frazer, PA, USA; eBiostatistics Teva Pharmaceuticals Ltd, Netanya, Israel; fBiostatistics Teva Pharmaceuticals Ltd, West Chester, PA, USA
hrp0084p2-415
Effects of GH Treatment on the Heart in Children with GH Deficiency
aUnidad de Cardiología Pediátrica (HURS), Córdoba, Spain; bGrupo PAIDI CTS-329 (IMIBIC), Córdoba, Spain; cServicio de Análisis Clínicos, Hospital Valle de los Pedroches, Córdoba, Spain; dServicio de Análisis Clínicos (HURS), Córdoba, Spain; eUnidad de Endocrinología Pediátrica, HURS (IMIBIC), Córdoba, Spain
hrp0084p2-416
GH Therapy in Skeletal Dysplasias: Final Height Data
Pediatric Endocrinology Program, Pediatric Unit, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
hrp0084p2-417
Random Forest Classification Predicts Response to Recombinant GH in GH Deficient Children Using Baseline Clinical Parameters and Genetic Markers
aFaculty of Medical and Human Sciences, Institute of Human Development, University of Manchester and Manchester Academic Health Science Centre, Royal Manchester Children’s Hospital, Manchester, UK; bQuartz Bio, Geneva, Switzerland; cGenizon BioSciences, St Laurent, Quebec, Canada; dMerck Serono, Darmstadt, Germany; eDepartment Pediatrie, Hôpital Mère-Enfant – Université Claude Bernard, Lyon, France
hrp0084p2-418
Safety Evaluation of Long-Term Recombinant GH Treatment in Childhood: Interim Analysis of the NordiNet[reg] International Outcome Study (IOS)
aAstrid Lindgren Children’s Hospital Q2:08, Karolinska University Hospital, Stockholm, Sweden; bNovo Nordisk Health Care AG, Zurich, Switzerland; cMedical Center, Saarland University, Homburg/Saar, Germany; dNovo Nordisk A/S, Søborg, Denmark; eTampere University Hospital, Tampere, Finland; fCharité – Universitätsmedizin Berlin, Berlin, Germany
hrp0084p2-419
Hypoglycaemic Adverse Events Reported in Children Enrolled in the European Increlex[reg] Growth Forum Database in Europe (5-Year Interim Data)
aUniversity of Bonn, Children’s Hospital, Bonn, Germany; bUniversité Paris Descartes, Hôpital Universitaire Necker Enfants Malades, Paris, France; cFaculty of Health Sciences, Linköping University, Linköping, Sweden; dIPSEN Pharma, Boulogne Billancourt, France
hrp0084p2-420
Application of Neural Networks for Final Height Prediction Based on Pre-Treatment Data in Children with GH Deficiency Treated with GH
aDepartment of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital – Research Institute, Lodz, Poland; bDepartment of Automatics and Biomedical Engineering, AGH University of Science and Technology, Krakow, Poland
hrp0084p2-421
Physical Performance and Right Ventricular Function in Children with GH Deficiency before and after 12 Months-GH Replacement Therapy
aDepartment of Translational Medical Sciences, University of Naples Federico II, Naples, Italy; bDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy
hrp0084p2-422
Timing of GH Peak in Provocation Tests is Important in Predicting the Effectiveness of Treatment with rhGH in Prepubertal Children with GHD
aFirst Paediatric Department, Aristotle University, Thessaloniki, Greece; bDepartment of Biochemistry, Hormone Assay Laboratory, Ippokratio General Hospital, Thessaloniki, Greece
hrp0084p2-424
rhGH Replacement Therapy Ameliorates Body Composition Substantially but has No Effect in the Quality of Life in Adolescents with GH deficiency - A Cross-Sectional Study
aUnit of Applied Research in Endocrinology and Diabetes, Athens University Medical School, Athens, Attiki, Greece; bFirst Department of Pediatrics, Athens University Medical School, Athens, Attiki, Greece; cBIOTEKNA, s.r.l., Venice, Italy
hrp0084p2-427
Evaluation of the Effect of GH Treatment on Insulin Resistance and Cardiovascular Tissue
aIstanbul Faculty of Medicine, Department of Pediatrics, Istanbul University, Istanbul, Turkey; bIstanbul Faculty of Medicine, Department of Cardiology, Istanbul University, Istanbul, Turkey; cIstanbul Faculty of Medicine, Division of Pediatric Endocrinology, Istanbul University, Istanbul, Turkey
hrp0084p2-428
Effectiveness of Recombinant IGF1 Treatment in a Patient with Isolated GH IA Deficit Producer of Anti-GH Antibodies
aHospital Sant Joan Reus, Reus, Spain; bHospital Clínic, Barcelona, Spain; cUniversity Hospital Leipzig, Leipzig, Germany
hrp0084p2-429
Analysis of CD133+CD45+ Hematopoietic Progenitor/Stem Cells and CD133+/CD45- Very Small Embryonic-Like Stem Cells in Children with GH Deficiency Subjected to GH Therapy
aDepartment of Pediatrics Endocrinology, Diabetology with the Cardiology Division, Medical University in Bialystok, Bialystok, Poland; bDepartment of Regenerative Medicine and Immune Regulation, Medical University, Bialystok, Poland; cDepartment of Hematology Diagnostic, Medical University in Bialystok, Bialystok, Poland; dDivision of Cardiology, Internal Affairs Ministry Hospital in Bialystok, Bialystok, Poland
hrp0084p2-430